• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿液和血浆蛋白质组学用于发现诊断糖尿病肾病与微小病变肾病或膜性肾病的生物标志物。

Urinary and plasma proteomics to discover biomarkers for diagnosing between diabetic nephropathy and minimal change nephrotic syndrome or membranous nephropathy.

作者信息

Araumi Akira, Osaki Tsukasa, Ichikawa Kazunobu, Kudo Kosuke, Suzuki Natsuko, Watanabe Sayumi, Watanabe Masafumi, Konta Tsuneo

机构信息

Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.

Department of Public Health and Hygiene, Yamagata University Faculty of Medicine, Yamagata, Japan.

出版信息

Biochem Biophys Rep. 2021 Aug 17;27:101102. doi: 10.1016/j.bbrep.2021.101102. eCollection 2021 Sep.

DOI:10.1016/j.bbrep.2021.101102
PMID:34458592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8379417/
Abstract

The choice of treatment for primary nephrotic syndrome depends on the pathologic type of the disorder. Renal biopsy is necessary for a definitive diagnosis, but it is burdensome for the patients, and can be avoided if tests could be performed using urine or plasma. In this study, we analyzed 100 urinary proteins, 141 plasma proteins, and 57 urine/plasma ratios in cases of diabetic nephropathy (DN; n = 11), minimal change nephrotic syndrome (MCNS; n = 14), and membranous nephropathy (MN; n = 23). We found that the combination of urinary retinol-binding protein 4 and SH3 domain-binding glutamic acid-rich-like protein 3 could distinguish between MCNS and DN, with an area under the curve (AUC) of 0.9740. On the other hand, a selectivity index (SI) based on serotransferrin and immunoglobulin G, which is often used in clinical practice, distinguished them with an AUC of 0.9091. Similarly, the combination of urinary afamin and complement C3 urine/plasma ratio could distinguish between MN and DN with an AUC of 0.9842, while SI distinguished them with an AUC of 0.8538. Evidently, the candidates identified in this study were superior to the SI method. Thus, the aim was to test these biomarkers for accurate diagnosis and to greatly reduce the burden on patients.

摘要

原发性肾病综合征的治疗选择取决于该疾病的病理类型。肾活检对于明确诊断是必要的,但对患者来说负担较重,如果能通过尿液或血浆进行检测则可避免。在本研究中,我们分析了糖尿病肾病(DN;n = 11)、微小病变肾病综合征(MCNS;n = 14)和膜性肾病(MN;n = 23)患者的100种尿蛋白、141种血浆蛋白以及57种尿/血浆比值。我们发现,尿视黄醇结合蛋白4和富含SH3结构域结合谷氨酸样蛋白3的组合能够区分MCNS和DN,曲线下面积(AUC)为0.9740。另一方面,临床实践中常用的基于血清转铁蛋白和免疫球蛋白G的选择性指数(SI)区分二者的AUC为0.9091。同样,尿α-胎儿蛋白和补体C3尿/血浆比值的组合区分MN和DN的AUC为0.9842,而SI区分二者的AUC为0.8538。显然,本研究中确定的候选指标优于SI方法。因此,目的是测试这些生物标志物以进行准确诊断并大幅减轻患者负担。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81b7/8379417/ba578287b2e3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81b7/8379417/79d87a68f1c4/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81b7/8379417/72b09489e708/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81b7/8379417/ba578287b2e3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81b7/8379417/79d87a68f1c4/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81b7/8379417/72b09489e708/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81b7/8379417/ba578287b2e3/gr2.jpg

相似文献

1
Urinary and plasma proteomics to discover biomarkers for diagnosing between diabetic nephropathy and minimal change nephrotic syndrome or membranous nephropathy.尿液和血浆蛋白质组学用于发现诊断糖尿病肾病与微小病变肾病或膜性肾病的生物标志物。
Biochem Biophys Rep. 2021 Aug 17;27:101102. doi: 10.1016/j.bbrep.2021.101102. eCollection 2021 Sep.
2
Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria.尿脂肪酸结合蛋白 4 水平作为一种可能的生物标志物在肾病范围内蛋白尿患者中用于微小病变病的识别的意义。
BMC Nephrol. 2020 Nov 3;21(1):459. doi: 10.1186/s12882-020-02122-y.
3
Potential urine proteomics biomarkers for primary nephrotic syndrome.原发性肾病综合征潜在的尿液蛋白质组学生物标志物
Clin Proteomics. 2017 May 16;14:18. doi: 10.1186/s12014-017-9153-1. eCollection 2017.
4
Biomarker discovery in glomerular diseases using urinary proteomics.利用尿蛋白质组学发现肾小球疾病的生物标志物。
Proteomics Clin Appl. 2008 Oct;2(10-11):1413-21. doi: 10.1002/prca.200800036. Epub 2008 Aug 28.
5
Complement activation products in the urine from proteinuric patients.蛋白尿患者尿液中的补体激活产物。
J Am Soc Nephrol. 2000 Apr;11(4):700-707. doi: 10.1681/ASN.V114700.
6
Comparison of lipid and fatty acid metabolism between minimal change nephrotic syndrome and membranous nephropathy.微小病变型肾病与膜性肾病脂质及脂肪酸代谢的比较
In Vivo. 2006 Nov-Dec;20(6B):891-3.
7
[Clinical significance of urinary cholesterol/total protein ratio as a marker of selectivity of proteinuria: comparison with selectivity index].尿胆固醇/总蛋白比值作为蛋白尿选择性标志物的临床意义:与选择性指数的比较
Rinsho Byori. 2009 Feb;57(2):118-23.
8
A Study of Clinical Presentation and Correlative Histopathological Patterns in Renal Parenchymal Disease.肾实质疾病的临床表现及相关组织病理学模式研究
Indian J Nephrol. 2018 Jan-Feb;28(1):28-34. doi: 10.4103/ijn.IJN_256_16.
9
[Two-color analysis of lymphocyte subpopulations in membranous nephropathy and minimal change nephrotic syndrome].膜性肾病和微小病变型肾病综合征中淋巴细胞亚群的双色分析
Nihon Jinzo Gakkai Shi. 1989 Aug;31(8):797-806.
10
Lectin-like oxidized LDL receptor-1 (LOX-1) expression in the tubulointerstitial area likely plays an important role in human diabetic nephropathy.凝集素样氧化型低密度脂蛋白受体1(LOX-1)在肾小管间质区域的表达可能在人类糖尿病肾病中起重要作用。
Intern Med. 2009;48(4):189-94. doi: 10.2169/internalmedicine.48.1251. Epub 2009 Feb 16.

引用本文的文献

1
The Spectrum of Minimal Change Disease/Focal Segmental Glomerulosclerosis: From Pathogenesis to Proteomic Biomarker Research.微小病变病/局灶节段性肾小球硬化症的谱系:从发病机制到蛋白质组学生物标志物研究
Int J Mol Sci. 2025 Mar 9;26(6):2450. doi: 10.3390/ijms26062450.
2
Complement classical and alternative pathway activation contributes to diabetic kidney disease progression: a glomerular proteomics on kidney biopsies.补体经典及替代途径激活促进糖尿病肾病进展:一项基于肾活检的肾小球蛋白质组学研究
Sci Rep. 2025 Jan 2;15(1):495. doi: 10.1038/s41598-024-84900-4.
3
Targeted MRM Quantification of Urinary Proteins in Chronic Kidney Disease Caused by Glomerulopathies.

本文引用的文献

1
Proteomics Applications in Health: Biomarker and Drug Discovery and Food Industry.蛋白质组学在健康领域的应用:生物标志物与药物发现及食品工业
Iran J Pharm Res. 2018 Fall;17(4):1523-1536.
2
Complement activation in patients with diabetic nephropathy.糖尿病肾病患者的补体激活。
Diabetes Metab. 2019 Jun;45(3):248-253. doi: 10.1016/j.diabet.2018.04.001. Epub 2018 Apr 16.
3
The modern spectrum of biopsy-proven renal disease in Chinese diabetic patients-a retrospective descriptive study.中国糖尿病患者经活检证实的肾脏疾病的现代谱——一项回顾性描述性研究。
靶向 MRM 定量检测肾小球病变引起的慢性肾脏病患者尿液中的蛋白质
Molecules. 2023 Apr 9;28(8):3323. doi: 10.3390/molecules28083323.
4
Antidiabetic effects of supplementation on biochemical parameters, inflammatory responses, and oxidative stress in canine diabetes.补充剂对犬糖尿病生化参数、炎症反应和氧化应激的抗糖尿病作用。
Front Pharmacol. 2023 Feb 14;14:1077228. doi: 10.3389/fphar.2023.1077228. eCollection 2023.
5
Impaired Organokine Regulation in Non-Diabetic Obese Subjects: Halfway to the Cardiometabolic Danger Zone.非糖尿病肥胖患者的器官因子调节受损:迈向代谢危险区的中途。
Int J Mol Sci. 2023 Feb 18;24(4):4115. doi: 10.3390/ijms24044115.
6
Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics.从蛋白质组学推断糖尿病肾病的分子途径
Diabetes Metab Syndr Obes. 2023 Jan 12;16:117-128. doi: 10.2147/DMSO.S392888. eCollection 2023.
7
Proteomic profiling and correlations with clinical features reveal biomarkers indicative of diabetic retinopathy with diabetic kidney disease.蛋白质组学分析及与临床特征的相关性研究揭示了糖尿病肾病伴糖尿病视网膜病变的生物标志物。
Front Endocrinol (Lausanne). 2022 Oct 5;13:1001391. doi: 10.3389/fendo.2022.1001391. eCollection 2022.
8
Urinary complement proteins are increased in children with IgA vasculitis (Henoch-Schönlein purpura) nephritis.尿补体蛋白在 IgA 血管炎(过敏性紫癜肾炎)患儿中增加。
Pediatr Nephrol. 2023 May;38(5):1491-1498. doi: 10.1007/s00467-022-05747-3. Epub 2022 Oct 13.
9
Pursuing Diabetic Nephropathy through Aqueous Humor Proteomics Analysis.通过房水蛋白质组学分析来研究糖尿病肾病。
Oxid Med Cell Longev. 2022 Sep 29;2022:5945828. doi: 10.1155/2022/5945828. eCollection 2022.
10
The Clinical Significance of Urinary Retinol-Binding Protein 4: A Review.尿视黄醇结合蛋白 4 的临床意义:综述。
Int J Environ Res Public Health. 2022 Aug 11;19(16):9878. doi: 10.3390/ijerph19169878.
PeerJ. 2018 Mar 27;6:e4522. doi: 10.7717/peerj.4522. eCollection 2018.
4
Update on Diabetic Nephropathy: Core Curriculum 2018.糖尿病肾病更新:2018 年核心课程。
Am J Kidney Dis. 2018 Jun;71(6):884-895. doi: 10.1053/j.ajkd.2017.10.026. Epub 2018 Feb 3.
5
Revisiting biomarker discovery by plasma proteomics.重新审视血浆蛋白质组学的生物标志物发现。
Mol Syst Biol. 2017 Sep 26;13(9):942. doi: 10.15252/msb.20156297.
6
Primary Membranous Nephropathy.原发性膜性肾病
Clin J Am Soc Nephrol. 2017 Jun 7;12(6):983-997. doi: 10.2215/CJN.11761116. Epub 2017 May 26.
7
Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.利用尿蛋白质组分析进行慢性肾脏病的无创诊断。
Nephrol Dial Transplant. 2017 Dec 1;32(12):2079-2089. doi: 10.1093/ndt/gfw337.
8
Minimal Change Disease.微小病变性肾病。
Clin J Am Soc Nephrol. 2017 Feb 7;12(2):332-345. doi: 10.2215/CJN.05000516. Epub 2016 Dec 9.
9
Urine Proteomics in the Era of Mass Spectrometry.质谱时代的尿液蛋白质组学
Int Neurourol J. 2016 Nov;20(Suppl 2):S70-75. doi: 10.5213/inj.1612720.360. Epub 2016 Nov 22.
10
Urinary Markers of Tubular Injury in Early Diabetic Nephropathy.早期糖尿病肾病肾小管损伤的尿液标志物
Int J Nephrol. 2016;2016:4647685. doi: 10.1155/2016/4647685. Epub 2016 May 16.